Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Idoxifene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 6/20 | 1.00 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 1.00 |
| ▸ | PDE1A | P54750 | 9/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 9/20 | 1.00 |
| ▸ | PDE1C | Q14123 | 9/20 | 1.00 |
| ▸ | PSMB1 | P20618 | 7/20 | 0.89 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.89 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Idoxifene SCHEMBL19217 | 1.00 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| Idoxifene SCHEMBL19216 | 1.00 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL8767418 | 0.95 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL8767423 | 0.95 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL8767419 | 0.95 | PDE1A (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL29822053 | 0.94 | PSMB1 (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL7650156 | 0.94 | PSMB1 (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL15648408 | 0.94 | PSMB1 (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL7650153 | 0.94 | PSMB1 (1.00) | PDE1APDE1BPDE1CESR1ESR2 | |
| SCHEMBL30902018 | 0.94 | PSMB1 (1.00) | PDE1APDE1BPDE1CESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11576891-B2 | Methods of treating or preventing estrogen-related diseases | ENDORECHERCHE, INC. | 2023-02-14 | — | — | US | disclosed |
| US-11452731-B2 | Method of treating and preventing loss of cognition | ENDORECHERCHE, INC. | 2022-09-27 | — | — | US | disclosed |
| EP-3682880-A1 | TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | Endorecherche, Inc. (CA) | 2020-07-22 | — | — | EP | disclosed |
| US-10548903-B2 | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM | ENDORECHERCHE, INC. (CA) | 2020-02-04 | — | — | US | disclosed |
| US-20190269696-A1 | METHOD OF PREVENTING ALZHEIMIER'S DISEASE | ENDORECHERCHE, INC. (CA) | 2019-09-05 | — | — | US | disclosed |
| US-20190269697-A1 | A METHOD OF TREATING AND PREVENTING LOSS OF COGNITION | ENDORECHERCHE, INC. (CA) | 2019-09-05 | — | — | US | disclosed |
| US-10342805-B2 | Treatment of Alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators | ENDORECHERCHE, INC. (CA) | 2019-07-09 | — | — | US | disclosed |
| US-20170290847-A1 | TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM | ENDORECHERCHE, INC. | 2017-10-12 | — | — | US | disclosed |
| US-9744177-B2 | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM | ENDORECHERCHE, INC. (CA) | 2017-08-29 | — | — | US | disclosed |
| EP-3178480-A1 | TREATMENT OF HOT FLUSHES, VASOMOTOR SYMPTOMS, AND NIGHT SWEATS WITH SEX STEROID PRECURSORS IN COMBINATION WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS | Endorecherche, Inc. (CA) | 2017-06-14 | — | — | EP | disclosed |
| US-20020198179-A1 | Selective estrogen receptor modulators in combination with estrogens | ENDORECHERCHE, INC. | 2002-12-26 | — | — | US | disclosed |
| US-20020182659-A1 | Method to determine TGF-beta | NEORX CORPORATION | 2002-12-05 | — | — | US | disclosed |
| US-6410587-B1 | FIBROSIS; ALZHEIMER'S DISEASE; ANTIARTHRITIC AGENTS | NEORX CORPORATION | 2002-06-25 | — | — | US | disclosed |
| US-20020068731-A1 | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues | NEORX CORPORATION | 2002-06-06 | — | — | US | disclosed |
| US-6395494-B1 | SCREENING BLOOD SAMPLE FOR LIGAND BOUND TRANSFORMING GROWTH FACTOR; OBTAIN MAMMALIAN BLOOD, INCUBATE WITH BINDING PARTICLE, INCUBATE WITH DETECTION PARTICLE, DETECT BOUND COMPLEX, DETERMINE SENSITIVTY TOATHEROSCLEROSIS | NEORX CORPORATION | 2002-05-28 | — | — | US | disclosed |
| US-6262079-B1 | TREATING NON-AORTAL PROCEDURAL VASCULAR TRAUMA COMPRISING ADMINISTERING TO A MAMMAL AN EFFECTIVE CYTOSTATIC ANTIPROLIFERATIVE AMOUNT OF A STRUCTURAL ANALOG OF TAMOXIFEN, OR A PHARMACEUTICALLY ACCEPTABLE SALT | NEORX CORPORATION | 2001-07-17 | — | — | US | disclosed |
| US-6251920-B1 | ADMINISTERING TAMOXIFEN OR ITS STRUCTURAL ANALOGS FOR PROPHYLAXIS AND THERAPY OF ATHEROSCLEROSIS, THROMBOSIS, MYOCARDIAL INFARCTION AND STROKE | NEORX CORPORATION | 2001-06-26 | — | — | US | disclosed |
| US-6197789-B1 | ANTIDIABETIC AGENTS | NEORX CORPORATION | 2001-03-06 | — | — | US | disclosed |
| US-6117911-A | ADMINISTRATION OF AT LEAST ONE THERAPEUTIC AGENT THAT ELEVATES THE LEVEL OF TGF-BETA IN SAID MAMMAL. | NEORX CORPORATION (US) | 2000-09-12 | — | — | US | disclosed |
| US-5595722-A | TRANSFORMING GROWTH FACTOR-BETA ACTIVATORS | NEORX CORPORATION (US) | 1997-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190269697-A1 | A METHOD OF TREATING AND PREVENTING LOSS OF COGNITION | SHBG, BRCA1, CYP19A1 | ESR1 15/4885ESR2 5/4885PDE1A 664/4885 |
| US-20020198179-A1 | Selective estrogen receptor modulators in combination with estrogens | KISS1R, ESR1, BRCA1 | ESR1 2/4885ESR2 8/4885PDE1A 462/4885 |
| US-20190269696-A1 | METHOD OF PREVENTING ALZHEIMIER'S DISEASE | BRCA1, SHBG, CYP19A1 | ESR1 11/4885ESR2 5/4885PDE1A 1193/4885 |
| US-11452731-B2 | Method of treating and preventing loss of cognition | SHBG, BRCA1, CYP19A1 | ESR1 11/4885ESR2 6/4885PDE1A 653/4885 |
| US-10342805-B2 | Treatment of Alzheimer's disease, loss of cognition, memory loss and dementia with sex steroid precursors in combination with selective estrogen receptor modulators | BRCA1, SHBG, CYP19A1 | ESR1 5/4885ESR2 6/4885PDE1A 635/4885 |
| US-10548903-B2 | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM | SHBG, CYP19A1, AR | ESR1 52/4885ESR2 46/4885PDE1A 276/4885 |
| US-20170290847-A1 | TREATMENT OF MALE ANDROGEN DEFICIENCY SYMPTOMS OR DISEASES WITH SEX STEROID PRECURSOR COMBINED WITH SERM | SHBG, CYP19A1, AR | ESR1 52/4885ESR2 46/4885PDE1A 276/4885 |
| US-11576891-B2 | Methods of treating or preventing estrogen-related diseases | SHBG, ESRRA, ESR2 | ESR1 8/4885ESR2 3/4885PDE1A 1842/4885 |
| US-20020068731-A1 | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues | TGFB1, TGFB2, TGFBR1 | ESR1 63/4885ESR2 28/4885PDE1A 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.